Rick Yang bought $2.3M of Korro Bio (KRRO)
Executed Mar 10, disclosed Mar 13, 2 days later.
Over the 21 trading sessions from the disclosed entry session (Mar 12), the stock returned +10.6% (delay-adjusted); from the execution session (Mar 10), +10.1%. Derived: entry at the session's open, exit at the close 20 sessions later.
Rick Yang (10% owner) filed 2 Form 4 reports in the trailing twelve months (2 purchases, 0 sales), most often in Korro Bio, Inc. (KRRO). Across 2 priced purchase filings, the average 21-session return was +8.1% from execution and +2.5% from disclosure (delay-adjusted; derived). The largest single filing was $15.0M of SGP (937,500 sh × $16.00, as filed), executed Feb 9.
Healthcare · Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on edi…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→